Pascal Deschatelets, Chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 7,896 shares at $30.43 ($240K) on 2025-01-22, disclosed to the SEC on 2025-01-23.
Seasonal sale ($240k) by Chief Scientific Officer — this insider has traded APLS in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.43 | 3,948 | $120K | 50.0% |
| 2 | $30.43 | 3,948 | $120K | 50.0% |
| Total | $30.43 avg | 7,896 | $240K | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $51K | — | Filing → |
| APLS | SELL | 2025-01-30 | $24K | — | Filing → |
| APLS | SELL | 2025-01-21 | $22K | — | Filing → |